Recovery of chronic renal impairment with sirolimus after lung transplantation

Annals of Thoracic Surgery

Volumn 78, Issue 6, 2004, Pages 1940-1943

  Venuta, Federico ^a,c   De Giacomo, Tiziano ^a   Rendina, Erino A ^a   Quattrucci, Serena ^b   Mercadante, Edoardo ^a   Cimino, Giuseppe ^b   Ibrahim, Moshen ^a   Diso, Daniele ^a   Bachetoni, Alessandra ^c   Coloni, Giorgio F ^a  

^a Department of Thoracic Surgery ^*  (Italy)

^b Cystic Fibrosis Center   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

12

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; MEPREDNISONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; BRONCHIOLITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; EPISTAXIS; FEMALE; FOLLOW UP; GRAFT REJECTION; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LARYNX CANCER; LEUKOPENIA; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MALE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; UREMIA;

ADULT; CALCINEURIN; CHRONIC DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 9344255454     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2004.03.018     Document Type: Article

References (19)

1. Brockroelofs J., Navis G.J., Stegeman C.A., et al. Long term renal outcome after lung transplantation is predicted by the 1 month postoperative renal function loss. Transplantation. 69:2000;1624-1628
2. Goldstein D.J., Zuech N., Sehgal V., Weinberg A.D., Drusin R., Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Incidence and prognosis. Transplantation. 63:1997;664-668
3. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the International Society for Heart and Lung Transplantation nineteenth official report - 2002. J Heart Lung Transplant. 21:2002;950-970
4. Olyaei A.J., De Mattos A.M., Bennett W.M. Immunosuppressant induced nephropathy. Drug Saf. 21:1999;471-488
5. Johnson R.W.G., Kreis H., Oberbauer R., Brattstrom C., Claesson K., Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 72:2001;777-786
6. Snell G.I., Levvey B.J., Chin W., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant. 21:2002;540-546
7. Snell G.I., Levvey B.J., Kotsimbos A.T.C., et al. Rescue therapy a role for sirolimus in lung and heart transplant recipients. Transpl Proc. 33:2001;1084-1086
8. Cooper J.D. Lung transplantation a new era. Ann Thorac Surg. 44:1987;447-448
9. Bennett W.M., De Mattos A., Meyer M.M., Andoth T., Barry J.M. Chronic cyclosporine nephropathy the Achilles' heel of immunosuppressive therapy. Kidney Int. 50:1996;1089-1100
10. Andoth T.F., Burdman E.A., Bennett W.M. Nephrotoxicity of immunosuppressive drugs experimental and clinical observations. Semin Nephrol. 17:1997;34-45
11. Kreis H., Cisterne J., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 69:2000;1252-1260
12. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin) based therapy in human renal transplantation. Similar efficacy and different toxicity compared with cyclosporine. Transplantation. 67:1999;1036-1042
13. Kahan B. Sirolimus a new agent for clinical renal transplantation. Transpl Proc. 29:1997;48-50
14. Valentine V.G., Robbins R.C., Berry G.J., et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant. 15:1996;371-383
15. Nathan S.D., Ross D.J., Bleman M.J., et al. Bronchiolitis obliterans in single lung transplant recipients. Chest. 107:1995;967-972
16. Nair R.V., Huang X., Shorthouse R., et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative bronchiolitis in vivo. Transplant Proc. 29:1997;614-615
17. Cahill B.C., Somerville K.T., Crompton J.A., et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant. 22:2003;169-176
18. King-Biggs M.B., Dumitz J.M., Park S.J., Savik S.K., Herz M.I. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 75:2003;1437-1443
19. Dutly A.E., Gaspert A., Inci I., Schneiter D., Korom S., Weder W. The influence of the rapamycin-derivative SDZ RAD on the healing of airway anastomosis. Eur J Cardiothorac Surg. 24:2003;154-158